A New Era in Prostate Cancer Treatment? Understanding the Therapeutic Rationale for PARP Inhibition

Join us for this interactive symposium, where Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD; Emmanuel S. Antonarakis, MBBCh; and Heather H. Cheng, MD, PhD, provide their perspectives on PARP inhibitors in prostate cancer, including insights into their development, review of available clinical data, and how these agents may affect management strategies for patients with prostate cancer in the future.

Sign up now! Registration is complimentary.

Not an official event of the 2018 Genitourinary Cancers Symposium. Not sponsored, endorsed, or accredited by ASCO or the Conquer Cancer Foundation.


6:30 PM - 7:00 PM Dinner and Registration

7:00 PM - 7:10 PM Welcome and Introduction

7:10 PM - 7:30 PM Overview of DNA Repair Mechanisms and the Molecular Landscape of Advanced Prostate Cancer Emmanuel S. Antonarakis, MBBCh

  • The role of DNA repair defects on prostate cancer carcinogenesis and progression

7:30 PM - 8:10 PM DNA Repair Defects as a Therapeutic Target in Prostate Cancer: The Role of PARP Inhibitors Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD (Program Director)

  • Clinical development of PARP inhibitors in BRCA1/2-mutant or homologous recombination–deficient prostate cancer
  • Ongoing clinical trials and combination strategies in prostate cancer with DNA repair mutations or homologous recombination deficiency

8:10 PM – 8:30 PM The Intersection of Germline and Somatic Genetic Testing in Advanced Prostate Cancer – Heather H. Cheng, MD, PhD

8:30 PM - 9:00 PM Challenges Moving Forward: Panel Discussion and Audience Questions and Answer Session


Date / Time
Event Details


Program Director
Johann Sebastian de Bono, MB, ChB, FRCP, MSc, PhD

Professor of Experimental Cancer Medicine 
Department of Medicine and Drug Development 
Institute of Cancer Research 
Honorary Consultant Medical Oncology 
Department of Medicine and Drug Development 
Royal Marsden Hospital NHS Foundation Trust 
Sutton, Surrey, United Kingdom

Emmanuel S. Antonarakis, MBBCh

Associate Professor
Department of Oncology
Johns Hopkins University
Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland

Heather H. Cheng, MD, PhD

Assistant Professor
Division of Oncology
Department of Medicine
University of Washington
Seattle, Washington

Goal Statement
The goal of this activity is to improve participants’ knowledge of BRCA and other DNA repair gene testing as well as competence in applying the latest data on PARP inhibitors to optimize the treatment of patients with prostate cancer.

Target Audience
This program is intended for oncologists, urologists, and other healthcare providers who care for patients with prostate cancer.

Learning Objectives

  • Describe the rationale and process for assessing germline and somatic DNA repair pathway alterations in prostate cancer
  • Examine the mechanism of PARP inhibition to achieve “synthetic lethality” in prostate cancer with deficient BRCA1/2
  • Evaluate the available clinical evidence for the use of PARP inhibitors to treat metastatic CRPC harboring BRCA1/2 or ATM mutations
  • Identify patients suitable for enrollment on ongoing clinical studies investigating PARP inhibitor monotherapy or in combination with other agents or therapies in prostate cancer


Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest
The Annenberg Center for Health Sciences at Eisenhower requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to the Annenberg Center for Health Sciences at Eisenhower policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.